Remove 2014 Remove Compounding Remove Magazine
article thumbnail

Why relationships are key in rare disease patient engagement

pharmaphorum

For nearly 25 years, Jeremy has focused on aiding the biopharmaceutical and health sciences industry in the development of key compounds and new therapies. George Underwood is the editor for pharmaphorum’s Deep Dive digital magazine. About the author.

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. They employed hundreds of new salespeople to detail doctors and hospitals, spent millions on TV and magazine ads and handed out masses of free samples. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog.